Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1262477
Disease: Weight decreased
Weight decreased 		0.100 Biomarker phenotype HPO
CUI: C1282971
Disease: von Willebrand Disease, Type 2B
von Willebrand Disease, Type 2B 		0.010 GeneticVariation disease BEFREE Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage. 27885890 2017
CUI: C3887875
Disease: Visual field defects
Visual field defects 		0.100 Biomarker group HPO
CUI: C0042571
Disease: Vertigo
Vertigo 		0.100 Biomarker phenotype HPO
CUI: C0042487
Disease: Venous Thrombosis
Venous Thrombosis 		0.100 Biomarker phenotype HPO
CUI: C0042029
Disease: Urinary tract infection
Urinary tract infection 		0.010 Biomarker group BEFREE Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis. 25562574 2015
CUI: C1519680
Disease: Tumor Immunity
Tumor Immunity 		0.010 Biomarker phenotype BEFREE Here, DDA/MPL and an adenovirus prime-protein boost strategy were applied to enhance the specific anti-tumor immunity of a truncated survivin protein vaccine. 23624214 2013
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.010 AlteredExpression phenotype BEFREE Knockdown of CD110 expression significantly attenuated cell migration and invasion. 30770989 2019
CUI: C0007787
Disease: Transient Ischemic Attack
Transient Ischemic Attack 		0.100 Biomarker disease HPO
CUI: C0040264
Disease: Tinnitus
Tinnitus 		0.100 Biomarker phenotype HPO
CUI: C0040053
Disease: Thrombosis
Thrombosis 		0.020 GeneticVariation phenotype LHGDN MPL mutations lacked prognostic significance with respect to thrombosis, major hemorrhage, myelofibrotic transformation or survival. 18451306 2008
CUI: C0040053
Disease: Thrombosis
Thrombosis 		0.020 AlteredExpression phenotype LHGDN Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels. 15951300 2005
CUI: C0836924
Disease: Thrombocytosis
Thrombocytosis 		0.500 Biomarker disease BEFREE The recently characterized protein-protein interaction of CALR mutants and MPL receptor has advanced our knowledge on the functional role of CALR mutants in thrombocythemia but it has also uncovered limitations of the current established research models. 28589084 2017
CUI: C0836924
Disease: Thrombocytosis
Thrombocytosis 		0.500 GeneticVariation disease LHGDN JAK2 and MPL mutations in myeloproliferative neoplasms. 18566540 2008
CUI: C0836924
Disease: Thrombocytosis
Thrombocytosis 		0.500 GeneticVariation disease BEFREE Recently, germline mutations in Janus kinase 2 (JAK2) and MPL, two genes frequently mutated in sporadic MPD, have been shown to cause inherited thrombocytosis. 25195195 2014
CUI: C0836924
Disease: Thrombocytosis
Thrombocytosis 		0.500 GeneticVariation disease BEFREE Refractory anemia with ring sideroblasts (RARS-T) associated with marked thrombocytosis is a myelodysplastic/myeloproliferative neoplasm associated with both SF3B1 and JAK2 or MPL mutations. 24507814 2013
CUI: C0836924
Disease: Thrombocytosis
Thrombocytosis 		0.500 GeneticVariation disease BEFREE MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count. 17194663 2006
CUI: C0836924
Disease: Thrombocytosis
Thrombocytosis 		0.500 GeneticVariation disease BEFREE The thrombopoietin receptor (MPL) has been shown to be mutated (MPL W515L) in myelofibrosis and thrombocytosis yet new approaches to treat this disorder are still required. 26919114 2016
CUI: C0836924
Disease: Thrombocytosis
Thrombocytosis 		0.500 GeneticVariation disease BEFREE Given their diagnostic relevance, it is also beneficial and relatively straightforward to screen JAK2 V617F negative patients for JAK2 exon 12 mutations (in the case of erythrocytosis) or MPL exon 10 mutations (thrombocytosis or myelofibrosis) using appropriate assays. 23057517 2013
CUI: C0836924
Disease: Thrombocytosis
Thrombocytosis 		0.500 Biomarker disease CTD_human Primary and secondary thrombocytosis in childhood. 15813844 2005
CUI: C0836924
Disease: Thrombocytosis
Thrombocytosis 		0.500 Biomarker disease HPO
CUI: C0836924
Disease: Thrombocytosis
Thrombocytosis 		0.500 AlteredExpression disease BEFREE A decrease in expression of the Mpl protein can cause thrombocytosis even in the absence of mutations in the coding sequence, due to a shift in the balance between stimulation of signaling in megakaryopoiesis and removal of thrombopoietin by receptor mediated internalization in platelets. 20008195 2009
CUI: C0836924
Disease: Thrombocytosis
Thrombocytosis 		0.500 GeneticVariation disease LHGDN MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500 x 10(9)/l. 18040685 2008
CUI: C0836924
Disease: Thrombocytosis
Thrombocytosis 		0.500 GeneticVariation disease LHGDN K39N represents an identified functional Mpl polymorphism and is associated with altered protein expression of Mpl and a clinical phenotype of thrombocytosis. 15269348 2004
CUI: C0836924
Disease: Thrombocytosis
Thrombocytosis 		0.500 GeneticVariation disease BEFREE By contrast, MPL gene mutations were not associated with erythrocytosis, but segregated primarily with the phenotypes of thrombocytosis, extramedullary disease, myelofibrosis, and osteosclerosis. 17920755 2007